TY - JOUR
T1 - Adjuvant Chemotherapy for Early-Stage Breast Cancer
AU - McArthur, Heather L.
AU - Hudis, Clifford A.
PY - 2007/4
Y1 - 2007/4
N2 - Systemic chemotherapy is an integral component of the adjuvant treatment strategy for women who have early-stage breast cancer and accounts for significant improvements in breast cancer-specific mortality. Decisions regarding adjuvant therapy are increasingly complex with the advent of new therapeutic strategies, a growing body of literature on the molecular biology and natural history of breast cancer, and advances in therapeutic techniques and early detection. Ultimately, the risk-benefit calculus will continue to evolve in response to these advances and one hopes that clinicians will soon be able to tailor treatment recommendations to the biology of an individual cancer and the needs of the affected individual.
AB - Systemic chemotherapy is an integral component of the adjuvant treatment strategy for women who have early-stage breast cancer and accounts for significant improvements in breast cancer-specific mortality. Decisions regarding adjuvant therapy are increasingly complex with the advent of new therapeutic strategies, a growing body of literature on the molecular biology and natural history of breast cancer, and advances in therapeutic techniques and early detection. Ultimately, the risk-benefit calculus will continue to evolve in response to these advances and one hopes that clinicians will soon be able to tailor treatment recommendations to the biology of an individual cancer and the needs of the affected individual.
UR - http://www.scopus.com/inward/record.url?scp=34248578415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248578415&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2007.03.008
DO - 10.1016/j.hoc.2007.03.008
M3 - Review article
C2 - 17512445
AN - SCOPUS:34248578415
SN - 0889-8588
VL - 21
SP - 207
EP - 222
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 2
ER -